Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck.

ABSTRACT:

Background

Head and neck squamous cell carcinoma (HNSCC) is the most common type of tumor originating from the squamous epithelium of the oral cavity, oropharynx, larynx and hypopharynx. There is an urgent need to enhance therapeutic efficacy and ensure the function preservation of HNSCC treatment. This study aimed to evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in patients with resectable locally advanced HNSCC.

Methods

This was a prospective single-center, single-arm, open-label, phase II study involving patients with locally advanced HNSCC who were treated with pembrolizumab (200 mg) plus docetaxel (50 mg/m²) and cisplatin (50 mg/m²). After two cycles of the neoadjuvant chemoimmuno

SUBMITTER: Wang J 

PROVIDER: S-EPMC12753483 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature